Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target.

PubWeight™: 0.84‹?›

🔗 View Article (PMID 26073894)

Published in Tuberculosis (Edinb) on May 27, 2015

Authors

Sudha Ravishankar1, Anisha Ambady2, Disha Awasthy2, Naina Vinay Mudugal2, Sreenivasaiah Menasinakai2, Sandesh Jatheendranath2, Supreeth Guptha2, Sreevalli Sharma2, Gayathri Balakrishnan2, Radha Nandishaiah2, Vasanthi Ramachandran2, Charles J Eyermann3, Folkert Reck3, Suresh Rudrapatna2, Vasan K Sambandamurthy2, Umender K Sharma2

Author Affiliations

1: AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India. Electronic address: mailsuravi01@gmail.com.
2: AstraZeneca India Pvt. Ltd., Bellary Road, Hebbal, Bangalore 560024, India.
3: AstraZeneca Infection, Innovative Medicines, 35 Gatehouse Drive, Waltham, MA 02451, United States.